Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome

Olíva, Esther Natalie; Dimitrov, Borislav D.; Benedetto, Frank; D’Angelo, Arianna; Nobile, Francesco

doi:10.1016/j.leukres.2005.03.004

Cited by 73 publications

(57 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported a positive correlation between Hb levels and HRQoL [9,19,20,[24][25][26][27][28][29][30][31], although this correlation is not consistent [6]. The current data reinforce the notion of a relationship between Hb levels and QOL-E© as specific patient-reported outcome in MDS patients.…”

Section: Discussionsupporting

confidence: 40%

“…The draft item list was derived in a cross-sectional study of 52 MDS patients from Heart-MDS study [19] 11…”

Section: Qol-e© Developmentmentioning

confidence: 99%

“…QOL-E© V2.0 data was collected cross-sectionally at baseline in all studies, alongside other measures of clinical effect and HRQoL, such as the EORTC QLQ-C30 questionnaire. Some cross-sectional and longitudinal data have been reported separately [19][20][21][22].…”

Section: Figure 1 Factor Analysis Of the 48-item Draft Qol-e© Instrumentioning

confidence: 99%

See 2 more Smart Citations

Development and validation of QOL-E© instrument for the assessment of health-related quality of life in myelodysplastic syndromes

Olíva

Nobile

Dimitrov³

2013

Open Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 40%

“…The draft item list was derived in a cross-sectional study of 52 MDS patients from Heart-MDS study [19] 11…”

Section: Qol-e© Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Development and validation of QOL-E© instrument for the assessment of health-related quality of life in myelodysplastic syndromes

Olíva

Nobile

Dimitrov³

2013

Open Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…13 Among specific modular disease-oriented questionnaires, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire -C30 (EORTC QLQ-C30) has been used worldwide to evaluate QoL in cancer patients. 14,15 Recently, a health-related quality of life questionnaire for patients with hematologic diseases (QOL-E) has been reported and validated in patients affected by myelodysplastic syndromes; [16][17][18] its role in elderly patients with AML, which is closely related to myelodysplastic syndromes, is investigated in this study.…”

Section: Introductionmentioning

confidence: 99%

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

Olíva¹,

Nobile²,

Alimena³

et al. 2011

Haematologica

View full text Add to dashboard Cite

patients aged more than 60 years with de novo acute myeloid leukemia were enrolled in a prospective observational study. Two different quality of life instruments were employed: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire -C30 (EORTC QLQ-C30) and a health-related quality of life questionnaire for patients with hematologic diseases (QOL-E). ResultsForty-eight patients (42.4%) received intensive chemotherapy and 65 (57.6%) were given palliative treatments. Age greater than 70 years (P=0.007) and concomitant diseases (P=0.019) had a significant impact on treatment allocation. At diagnosis, general quality of life was affected [median QOL-E standardized score 54, interquartile range 46-70; median EORTC global score 50, interquartile range 41-66]. Most patients were given a good ECOG Performance Status (< 2), which did not correlate with the patients' perception of quality of life. At multivariate analysis, palliative approaches (P=0.016), age more than 70 years (P=0.013) and concomitant diseases (P=0.035) each had an independent negative impact on survival. In a multivariate model corrected for age, concomitant diseases and treatment option, survival was independently predicted by QOL-E functional (P=0.002) and EORTC QLQ-C30 physical function (P=0.030) scores. ConclusionsQuality of life could have an important role in elderly acute myeloid leukemia patients at diagnosis as a prognostic factor for survival and a potential factor for treatment decisions.Key words: AML, elderly, intensive chemotherapy, quality of life.Citation: Oliva EN, Nobile F, Alimena G, Ronco F, Specchia G, Impera S, Breccia M, Vincelli I, Carmosino I, Guglielmo P, Pastore D, Alati C, and

show abstract

“…In patients with CHF, anemia (present in 40% of these patients) is associated with increased mortality and morbidity [30]. Chronic anemia is associated with increased cardiac output, which eventually leads to cardiac remodeling and left ventricular hypertrophy [31,32]. Anemia can also intensify angina and contribute to a higher incidence of cardiovascular complications [30,31,33].…”

Section: Discussionmentioning

confidence: 99%

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes

2008

View full text Add to dashboard Cite

The International Prognostic Scoring System (IPSS) was created for evaluating clinical outcomes of patients with myelodysplastic syndromes (MDS). We evaluated the depth of cytopenias to determine whether this parameter could further refine the prognostic ability of the IPSS. Correlation was determined between the depth of cytopenias in 816 patients from the International MDS Risk Analysis Workshop database and patients' clinical features. Univariate analyses of hemoglobin (Hb), absolute neutrophil count, and platelet depth levels were assessed relative to the IPSS risk groups, refined French-American-British categories, cytogenetic groups, bone marrow blast percentage (%), age groups, overall survival (OS), and time to evolution of acute myeloid leukemia (AML). Multivariate analysis of different cytopenic levels was performed to determine whether depth of cytopenias was prognostically additive to the IPSS. All cytopenic categories had statistically significant rank correlations with IPSS, bone marrow blast %, and refined French-American-British categories. In multivariate analysis, Hb levels had additive prognostic value to the IPSS for evaluation of OS, but not time to AML, with greatest prognostic value in Intermediate-1 and Intermediate-2 categories. In contrast, platelet or absolute neutrophil count levels alone or in combination lacked additive prognostic value to the IPSS regarding OS or time to AML evolution. The depth of Hb level per se at the time of diagnosis has additive predictive value to the IPSS for OS in the intermediate-risk groups. This information should prove useful for aiding therapeutic decision-making, prognostic classification, and designing clinical trials for patients with MDS. Am. J. Hematol. 83:765-770, 2008. V

show abstract

Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome

Cited by 73 publications

References 8 publications

Development and validation of QOL-E© instrument for the assessment of health-related quality of life in myelodysplastic syndromes

Development and validation of QOL-E© instrument for the assessment of health-related quality of life in myelodysplastic syndromes

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes

Contact Info

Product

Resources

About